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Sitabja Mukherjee and Santosh K. Kar
Abstract
Curcuminoids inactivate Nuclear Factor-Kappa B (NF-κB), a key pro-inflamma-
tory transcription factor which is involved in inflammation and immune response in 
diseases like cancer. NF-κB activation is necessary to determine tumor microenviron-
ment which controls migration and metastatis of cancer cells through chemokines and 
their receptors and involvement of some cell adhesion molecules. Therefore inhibition 
of NF-κB by curcuminoids could be a new approach in treatment of cancer by immune 
modulation. Curcuminoids are not bioavailable and therefore there were problems in 
efficacy. Now by using bioavailable curcuminoid formulations the problem has been 
resolved to a great extent. Out of 49 placebo controlled double blind clinical trials 
using curcuminoids, 17 have been found to be successful. Therefore curcuminoids 
could be developed as an adjunct therapy for diseases like cancer to save human life.
Keywords: Curcuminoids, Inflammation, Immunomodulation, Human clinical trial
1. Introduction
Curcuminoids are natural polyphenolic compounds present in the rhizome of 
Curcuma longa plant which are responsible for the yellow color of turmeric and it’s 
medicinal properties [1]. Turmeric has been used for centuries not only to make 
Indian curry spicy but also for healing wounds, reducing pain and as antibacterial 
agent in our traditional system of medicine [2]. No one knew what component of 
turmeric was responsible for these medicinal properties till Vogel Peletier isolated 
the pigment from it in 1815 [3]. No structural studies could be done as the isolated 
pigment was found to be a mixture of oleoresin and oil. Finally Vogel A Jr. isolated the 
pure pigment in 1842 but he did not determine its structure [4]. After unsuccessful 
attempts by many chemists, Milobedzka J and Lampe V determined the chemical 
structure of curcumin to be diferuloylmethane and named it as curcumin in 1910 
almost hundred years after it was first isolated in 1815 [5]. Later the same group syn-
thesized the molecule in 1913 which established its structure firmly [6]. Subsequently 
K R Srinivasan developed chromatographic methods to separate curcumin and 
showed it to have three components [7, 8].
Using diverse extraction techniques and chromatographic methods which 
are coupled with sensitive mass spectrometric detection system to identify the 
extracted molecules we now know that turmeric contains atleast 235 specialized 
secondary metabolites which include 109 sesquiterpene and 68 monoterpene mol-
ecules besides the three Curcuminoid molecules which are the subject of discussion 
here [9]. The three molecules viz. Curcumin (which is the major Curcuminoid), 









































































































Structure and properties of curcuminoids present in turmeric.
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Figure 1. 
Tautomeric forms of curcumin.
minor components of turmeric appear to have many medicinal properties. A fourth 
molecule called Cyclocurcumin which in the absence of α, β-unsaturated β-diketone 
motif is not considered as a Curcuminoid but an analog of Curcumin, has recently 
been identified to be present in the rhizome in much less concentration but with 
some interesting medicinal properties (Table 1) [10]. Table 1 gives the structure of 
the four molecules and summarizes the chemical properties of the three curcumi-
noids and cyclocurcumin for comparison.
Each of the three curcuminoid molecules contains two aromatic o-methoxy 
phenolic groups, except BDMC which has only phenolic groups joined linearly through 
a seven carbon chain linker containing α, β-unsaturated β-diketone groups. The pres-
ence of this linker chain with the α, β-unsaturated β-diketone groups, a unique feature 
of curcuminoid molecules, allows the curcuminoids to remain either in the keto or enol 
form depending upon the ambient pH and exhibit biological activities (Figure 1) [11].
Every year more than 10 thousand papers are published worldwide describing 
the biological activity and therapeutic potential of Curcumin. Here we will discuss 
some of the properties of curcumin and will introduce the Curcuma longa plant. 
Curcuma longa has been cultivated in India and other south eastern countries with 
suitable weather and soil conditions for centuries [12]. Significant efforts have been 
made to understand the biosynthesis of these molecules in the rhizome and purify 
them from turmeric to study their chemistry. Efforts have been made to synthesize 
them in heterologous systems like E.coli and so that novel curcuminoids could 
be made and tested for their activities. We will also discuss how there has been 
concerted efforts to discredit curcumin as a lead molecule due to it’s poor ADMET 
(absorption, distribution, metabolism, excretion, and toxicology) properties 
inspite of credibility of successful traditional usage to emerge as new neutraceutical 
drugs against diseases [13].
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2. The Curcuma longa plant
Curcuma longa belongs to Zingiberaceae family which includes Zingiber offici-
nalis, the source of ginger another very useful herb [14]. Curcuma longa grows to a 
height of 1 m as an upright, perennial plant displaying bright foliage and colored 
flowers. The plant is sterile as it produces seeds which are not viable but Curcuma 
longa can be vigorously propagated by using the rhizomes of the plant [15]. It 
does not grow in the wild and is thought to have arisen by selection and vegetative 
propagation of a hybrid between wild plant Curcuma aromatica which is, native 
to India and some other closely related species [16]. It is estimated that the genus 
Curcuma contains between 80 and 117 species, the majority of which are found in 
Southeast Asia, but some of which can also be found in the Himalayas, Southern 
China, Australia, and the Pacific Islands [16, 17]. Carolus Linnaeus, the famous 
Swedish taxonomist, coined the name Curcuma for the genus and included it in his 
book Species Plantarum, which was published in the year 1753. The plant derives its 
name “curcuma” from the Arabic word Kurkum, in reference to the yellowish color 
of its root [17].
To thrive, Curcuma longa requires temperatures ranging from 200Celsius to 350 
Celsius, and significant rainfall during the monsoon season when it is cultivated 
[18]. Turmeric is best known for its culinary applications as a major component of 
curry powder, for which it has been dubbed “Indian saffron” as a cheaper alterna-
tive to the far more expensive saffron spice. Turmeric is also used in cosmetics 
and toiletries. Its active ingredient has a distinct earthy, slightly bitter, slightly hot 
peppery flavor and a mustardy smell. The genus Curcuma also contains a number of 
economically important species, such as C. angustifolia (short-leaved turmeric), C. 
zedoaria (also known as zedoary) and C. amada which is a slang term for “amazing” 
(mango ginger). Curcuma plants such as C ornata, which has beautiful green leaves 
and pinecone-like flowers of light pink color that lasts for a month, C elata, which 
can withstand cold climate conditions and produces extremely brilliant yellow 
flowers, and C petiolata ‘Emperor’ from Thailand, which produces pink colored 
flowers, are few examples which can be grown as house plants.
Erode, a city in the Indian state of Tamil Nadu, with suitable weather condi-
tions and rainfall is the world’s largest producer of turmeric and the world’s most 
important trading center for the spice, earning it the nickname “Turmeric City” in 
addition to Sangli, a town in the Indian state of Maharashtra, which too is another 
significant trading center for turmeric throughout Asia. In a year, India produces 
600,000 tons of turmeric, which accounts for 75% of the world’s total annual 
production of 800,000 tons. The rhizomes, which are underground stems that look 
like roots and have a brown surface with bright orange or yellow interior flesh, are 
processed to produce a lemon yellow powder known as turmeric.
3.  Extraction of curcuminoids from turmeric and it’s synthesis in the 
laboratory
The extraction of curcumin from turmeric has become of immense commercial 
interest due to health benefitting medicinal properties of curcumin. For the process 
to be commercially viable it should be efficient, simple and the end product should 
be suitable for human consumption. Since India is one of the largest producers 
of turmeric, quite naturally there are a lot of activities with respect to extraction 
of curcuminoids from turmeric on a commercial scale. Typically, the content of 
curcuminoids in turmeric ranges from 2%-9% of the total dry weight depending 
upon origin of the plant and the conditions of the soil where it is grown. Even 
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though Curcumin was first isolated as a pigment in the impure form by Vogel in the 
year 1815, the methods of curcuminoids extraction are being standardized till very 
recently. The most commonly used method for extracting curcumin from turmeric 
has been the employment of solvent extraction followed by column chromatogra-
phy for separating curcuminoids from other molecules that are extracted. Soxhlet 
extraction, ultrasonic extraction, microwave, zone-refining and dipping methods 
have been tried, and among these the Soxhlet, ultrasonic and microwave extrac-
tions are the most commonly employed methods [19]. Recently, it has been reported 
that pulse ultrasonic and microwave-assisted extraction methods are superior to 
continuous extraction methods. As there is an increase in the use of curcumin in 
dietary supplements, researchers are continually developing newer extraction 
methods in order to increase the yield and quality of the end product. Green bio 
based methods which do not use surfactants or solvent are also being developed. 
When compared with the conventional ethanol/water based extraction methods, 
the surfactant free microemulsion (SFME) methods have been found to be more 
efficient in extracting curcuminoids [20]. Some of the newer methods use food 
grade molecules like triacylglycerol which can solubilize curcumin in the presence 
of water for achieving higher yield and use of supercritical carbon dioxide makes 
it a method free of any organic solvents [21]. Pilot plants based on supercritical 
carbon dioxide have been established in several countries for the extraction of 
curcumin from turmeric with the purpose of making the extraction process of 
curcumin a commercially viable one.
Column chromatography can separate curcumin from curcumin mix (a mixture 
of curcumin, demethoxycurcumin, and bisdemethoxycurcumin) by adsorbing 
the mixture on silica gel and then eluting with solvent mixtures such as dichloro-
methane/acetic acid or methanol/chloroform to yield three different fractions. The 
curcumin fraction is then purified further on silica gel using eluents such as chlo-
roform/dichloromethane and ethanol/methanol mixtures. The high performance 
liquid chromatography (HPLC) technique has been used extensively in the detec-
tion and estimation of curcumin in different fractions. In general, reverse phase 
C18 columns are used as the stationary phase, with various gradients of solvents 
containing acetonitrile/water or chloroform/methanol used as the mobile phase 
[22]. Curcumin detection is simple and can be done by using absorption detectors 
in the visible range of 350 to 450 nm or in the UV region using a common detec-
tion wavelength in the range of 250 to 270 nm. Several researchers have also used 
HPLC-diode array and fluorescence detection methods. Another versatile tool for 
detecting curcumin is liquid chromatography-coupled mass spectrometry [23].
Lampe published the first paper on the synthesis of curcumin in 1918, a century 
after its isolation from turmeric. The procedure consisted of five steps, beginning 
with carbomethoxyferuloyl chloride and ending with ethyl acetoacetate. Later, 
Pabon reported a simpler method for the synthesis of curcumin in high yields using 
acetyl acetone and substituted aromatic aldehydes in the presence of boron trioxide 
(B2O3), trialkyl borate, and n-butylamine (Figure 2). This method was adopted 
by several research groups for all subsequent synthesis of curcumin with minor 
modifications. The primary step in all of these methods is the reaction of 2,4-dik-
etones with appropriately substituted aromatic aldehydes. To prevent the participa-
tion of diketone in Knoevenagel condensations, it is complexed with boron. These 
reactions are best performed in anhydrous conditions and polar aprotic solvents, 
where curcumin can be easily separated from reaction mixtures. Primary and 
secondary amines are used as catalysts to provide the basicity required to deproton-
ate the diketone’s alkyl groups. Scavengers such as alkyl borates are used to remove 
the water produced during the condensation reaction. Water, if not removed, can 
react with the diketone complex, reducing the curcumin yield. Under slightly acidic 
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conditions, the boron complex dissociates into curcumin. Washing and repeated 
precipitation followed by column chromatography can then be used to separate 
curcumin from this reaction mixture [24].
4. Chemistry of curcuminoids
The relative concentrations of the three curcuminoids in the turmeric vary 
depending upon the source of the rhizome used for propagation and the climatic 
conditions as well as fertility of the soil in which it is grown. Typically it varies 
between the following ranges: curcumin (70-80%), demethoxy curcumin (10-
20%), and bisdemethoxy curcumin (3-6%) [25]. Because curcumin is the primary 
curcuminoid found in turmeric, it could be playing a significant role in the control 
of the medicinal properties of the mixture. It is equally important that we should 
investigate how the other two molecules contribute to curcuminoids’ health  
benefitting effects like anti-inflammatory, anti-oxidant, and immunomodulatory  
properties [24].
Because the methylene group in curcumin contains two active hydrogen atoms 
and is flanked by two keto groups, the hydrogen atom attached to the carbon 
atom can migrate to the oxygen atom of the keto group, resulting in the keto-enol 
tautomeric forms (Figure 1) Extensive research over the last few decades have 
established the role of these distinct functional domains in curcumin’s observed 
biological activities.
When the pH is between 3 and 7, it is the keto form that is predominantly found 
embedded in the lipid bilayer of membranes, while the enol form is found around 
pH 8. Curcumin’s physicochemical and antioxidant properties are determined by 
this keto-enol-enol equilibrium. It is worth noting that when curcumin is present 
in the enol form, both aromatic rings at either end of the molecule can interact 
through extensive electron delocalization via the pi orbitals of the C=C bonds in the 
Figure 2. 
Laboratory synthesis of curcumin.
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heptadiene linker. Due to these structural constraints, the aromatic rings at either 
end of the molecule must be in the same plane, transforming the whole molecule 
into a planar structure.
The two aromatic rings with hydroxyl and O-methyl groups can exist in separate 
planes and interact with other molecules independently. The keto form exhibits 
distinct physiological properties, whereas the enol form, which must be planar, 
degrades rapidly [26]. When curcumin is administered orally or via intraperitoneal 
injection, it is rapidly eliminated through the feces due to its low solubility, which 
results in decreased absorption and extensive systemic clearance due to its degrada-
tion or metabolic conversion to more water-soluble forms that are rapidly secreted 
out. In the gut, curcumin is converted enzymatically to more soluble forms such as 
glucuronide and sulphate conjugates or reduced to tetrahydrocurcumin and hexa-
hydrocurcuminglucuronides [27].
Curcumin’s fundamental antioxidant activity is entirely dependent on the 
presence of hydrogen on the phenolic or central methylene groups. By losing a 
proton, a phenoxy-radical can be generated from the curcumin molecule’s phenolic 
groups, and similar reactions can generate a carbon radical from the central methy-
lene group. Although the phenoxy radical is more stable than the carbon radical, 
experimental data from study of curcumin indicate that both phenoxy and carbon 
radicals contribute to curcumin’s biological activity. The phenoxy or carbon radicals 
produced by curcumin molecules are resonance stabilized by extensive conjugation 
via the heptadiene linker. As a result, curcumin acts as a potent scavenger of various 
reactive oxygen species (ROS), including hydroxyl radicals, hydrogen peroxide, sin-
glet oxygen, and superoxide anion, thereby preventing damage to macromolecules 
in circulation or present in tissue. As a result, the phenolic groups or active methy-
lene groups are a critical component of the curcumin molecule which contribute to 
its bioactivity [28].
As with curcumin, the other two curcuminoids (demethoxycurcumin and bisde-
methoxycurcumin) also contain phenolic hydroxyl groups, a heptadiene chain, and 
a diketone moiety, which contribute to their diverse therapeutic properties, includ-
ing antioxidant, anti-inflammatory, and anticancer properties. Curcumin has the 
highest antioxidant capacity, followed by demethoxycurcumin and bisdemethoxyc-
urcumin. This observation holds true only when curcuminoids are not degraded, 
as is the case when an acidic or polar medium is used. On the other hand, under 
basic or non-polar conditions, bisdemethoxycurcumin is more stable than deme-
thoxycurcumin, which in turn is more stable than curcumin. Apart from pH or the 
nature of the medium the structure of the phenolic compounds has an effect on the 
stability of curcuminoids. The electron donating group like OH or OMe groups on 
the benzene rings has a preference for the enol tautomer. Thus, among the three 
curcuminoids, the equilibrium shifting toward formation of the enol tautomer is 
greatest for curcumin and least for bisdemethoxycurcumin due to the presence of 
two methoxy groups. Bisdemethoxycurcumin, on the other hand, is less susceptible 
to degradation than demethoxycurcumin, which is less susceptible to degradation 
than curcumin. In basic or non-polar solvents, the rate of degradation is as follows: 
curcumin >demethoxycurcumin> bisdemethoxycurcumin (Figure 3).
The activity of Curcuminoids is strongly influenced by the methoxy group. 
The antioxidant activity of curcuminoids is primarily due to the active methylene 
group; however, the presence of an electron-donating methoxy groups ortho to the 
phenolic hydroxyl group also contributes to the molecule’s antioxidant activity via 
an inductive effect on the hydroxyl group. Curcumin has the highest antioxidant 
activity of the three curcuminoids due to the presence of two methoxy groups. 
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Demethoxycurcumin has greater antioxidant activity than bisdemethoxycurcumin, 
which lacks a methoxy group.
5. Pharmacology of curcumin: role of degradation products
Curcumin is poorly bioavailable and fairly unstable in tissue under normal 
physiologic conditions. As a result, it is very likely that the metabolically trans-
formed curcumin products, which are relatively more water-soluble, are responsible 
for the observed health benefits of curcumin. It has been shown that 90% of 
curcumin degrades within 30 minutes in phosphate buffer (pH 7.4) into various 
products such as, trans-6-(4hydroxy-3-methoxyphenyl)-2,4-dioxo-5-hexanal, 
ferulic aldehyde, ferulic acid, feruloyl methane, vanillin, and a few others [29]. 
Degradation occurs in basic medium via nucleophilic attack of the basic -hydroxide 
ion. The alkaline hydrolysis of curcumin produces feruloylmethane and ferulic acid. 
Further hydrolysis of the feruloylmethane results in the formation of vanillin and 
acetone. Thus, under basic conditions, the heptadienone moiety is broken, resulting 
in the disappearance of the active methylene group that contributes tothe majority 
of curcumin’s antioxidant activity. Depending on the conditions it is subjected to, 
Curcumin can also undergo autoxidation or photooxidation to give rise to different 
degradation products (Figure 4).
Furthermore, it is unclear how curcumin exerts its inhibitory effects on such 
a large number of different enzymes whose binding pockets are unable to bind 
curcumin specifically. By comparing the biological activities of curcumin and its 
degradation products against diseases such as Alzheimer’s and cancer, as well as 
their preferential inhibition of certain enzymes, it appears as though the bioac-
tive degradation products may play a significant role in contributing to curcum-
in’s observed pharmacological effects [30]. On the other hand, when curcumin 
enters the bloodstream, it forms complexes with proteins such as Albumin  
etc. and gets stabilized [31]. As a result, the rapid degradation of curcumin 
Figure 3. 
Structure–function relationship of Curcuminoids.
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observed in the absence of proteins may not be occurring to the same extent in 
the tissue. This possibility should be investigated further in order to understand 
curcumin’s pharmacokinetics and beneficial effects in the treatment of various 
diseases.
6. Biosynthesis of curcuminoids in the rhizome
Three polyketide synthases (PKS) isoforms, CURS1, CURS2, and CURS3, 
found in the leaves and rhizomes of Curcuma longa are involved in catalyzing the 
synthesis of various curcuminoids using various feruloyldiketide-CoAs as starter 
substrates [32]. The Curcuminoid Biosynthetic Pathway in Curcuma longa rhizome 
was investigated using 13C-labeled precursors and the enzyme involved in the 
process. It has been demonstrated that CURS1 exclusively utilizes feruloyl-CoA as a 
starting substrate and converts feruloyldiketide-CoA esters to curcumin. Similarly, 
CURS2 produces both curcumin and demethoxycurcumin using feruloyl-CoA as 
a starter substrate, whereas CURS3 produces all three curcuminoids, curcumin, 
demethoxycurcumin, and bisdemethoxycurcumin, using either feruloyl-CoA or 
4-coumaroyl-CoA as the starter substrate [32].
Figure 4. 
Different paths for degradation of curcumin.
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Heterologous production of Curcuminoids has been attempted in E. coli and 
Saccharomyces cerevisiae. Katsuyama et al. prepared an E. coli strain with artificial 
biosynthetic pathway by combining enzyme-encoding genes such as 4-coumarate-
CoA ligase (4CL) from Lithospermumerythrorhizon (Le4CL1), curcuminoid synthase 
(CUS)from O. sativa and Acetyl-CoA carboxylase (ACC) from Corynebacterium glu-
tamicum which generated a new set of gene clusters which produced curcuminoids 
[33]. Using this approach and by adding two different unnatural carboxylic acids, 9 
new curcuminoids which are not found in nature could also be produced [34]. This 
precursor-driven biosynthetic approach allowed the production of unnatural novel 
polyketides. This way of producing unnatural curcuminoids may provide novel 
drug candidates.
The production of curcumin and its derivatives by CURS may be an adaptive 
mechanism employed by the Curcuma longa plant to both protect against and 
respond to a variety of threats. Curcumin is a potent antioxidant that acts as a 
scavenger of free radicals, removing them from the plant’s cells. Curcumin’s bitter 
taste may also serve as a deterrent to herbivores.
7. Can curcuminoids be lead molecules to be a drug?
In a spirited article Kathryn M. nelson et al. have pointed out that “curcumi-
nods which constitute about ∼5% of turmeric has been classified as pan-assay 
interference (PAINS) compounds as well as invalid metabolic panaceas (IMPS) 
candidate [35]. Further curcuminoids are nonbioavailable, unstable and reactive 
compounds. Therefore they arehighly improbable lead for development of any 
drug. They pointed out and I quote “To our knowledge, compound 1 has never 
been shown to be conclusively effective in a randomized, placebo-controlled 
clinical trial for any indication. Curcumin is best typified, therefore, as a missile 
that continually blows up on the launch pad, never reaching the atmosphere or its 
intended target (s). These results have given curcumin the label of pharmacody-
namically fierce (hits many targets) yet pharmacokinetically feeble (does not get 
to its targets). While these failures would normally end further research on its use 
as a therapeutic, they apparently have not deterred researchers interested in its 
development.”
Responding to this paper by Nelson et al., Padmanaban G. and Nagaraj V. 
wrote a paper entitled “Curcumin May Defy Medicinal Chemists” to remind Dr. 
Nelson that just taking 4 clinical trials on curcuminoids into consideration it is not 
proper to suggest that all research on Curcuminoids should be suspended [36]. 
They wrote and I quote “. With over 10,000 papers published and 120 clinical tri-
als under various stages of progress using curcumin, the review is a huge damp-
ener, considering the projected potential of curcumin and other natural products 
as a panacea. Even if 1% of the papers published make sense, it would still be a 
sizable number to warrant against passing a negative verdict on the whole field. 
The review has picked four clinical trials and concluded that given its low sys-
temic bioavailability, it is doubtful whether oral curcumin would ever be effective 
in human clinical trials.”
After this paper by Padmanaban et al. was published, Nelson et al. responded 
without realizing that their arguments are based on wrong interpretation of data 
generated by others [37]. Soon another paper was published pointing out that 
while some of the arguments about curcuminoids are true, many of the conclu-
sions drawn by Nelson et al. on the basis of referred papers are hard to accept as 
they were never made by the authors of these referred papers. The issue of cur-
cuminoids being PAINS compounds was insignificant unless it actually interferes 
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with the high-throughput screening employed. What actually matters at the end 
of the human clinical trials and case studies is whether human life could be saved 
for which nature has designed these molecules [38]. In a recent letter to editor 
of Nature Michal Heger writes not to discount all the curcumin trial data. He 
points out that out of 49 clinical trials conducted recently 17 have shown efficacy. 
Therefore the molecular targets and the mechanisms of action of curcumin should 
be examined further [39]. Curcuminoids are wonderful molecules and can be 
developed to play significant role as adjunct therapy against inflammatory diseases. 
The pace of research on curcumin has not slowed down in spite of the two papers by 
Nelson et al.
It has been demonstrated that when curcumin was bound to chitosan nano 
particles and delivered orally to mice infected with Plasmodium yoelii parasite, the 
treated mice survived longer than the infected untreated mice [40]. Curcumin 
alone could not do so. When it was adsorbed on to chitosan nano particles and fed 
orally it’s bioavailability increased and it entered into infected RBC and prevented 
hemozoin synthesis which killed the parasite.
In another experiment it was demonstrated that when nano curcumin alone 
was given orally to Mycobacterium tuberculosis infected mice it did not kill the 
Mycobacteria and the infected animals did not survive. But when it was adminis-
tered in the presence if INH it helped to cure the infected mice in five weeks while 
INH alone could cure only in 8 weeks [41]. Therefore the combination of nano 
curcumin with INH was more effective than INH alone.
In a third experiment it has been shown that nano curcumin when administered 
orally to mice can modulate memory T cells and induced immune response against 
BCG in a manner which does not happen in the absence of nano curcumin [42]. 
These papers showed that curcumin can modulate immune memory mechanisms 
which was effective in prevention of death.
8.  Human clinical trials with curcumin demonstrating efficacy  
of treatment
8.1 Curcumin for the prevention of colorectal neoplasia
Inhibition of the procarcinogenic eicosanoids prostaglandin E2 (PGE2) and 
5-hydroxyeicosatetraenoic acid (5-HETE) has been shown in rodent models to 
have the potential to suppress carcinogenesis. In a nonrandomized, open-label 
clinical trial involving 44 patients, Robert E. et al. evaluated the effects of 
oral curcumin administration (2 g or 4 g per day for 30 days) on PGE2 within 
aberrant crypt foci (ACF), 5-HETE, ACF number, and proliferation [43]. To be 
eligible, men and women had to be at least 40 years old, a current smoker with 
a smoking history of more than three pack-years, and have at least eight rectal 
ACF detected using magnification chromoendoscopy. Subjects were excluded if 
they used nonsteroidal antiinflammatory drugs (NSAIDs), such as acetylsalicylic 
acid (ASA, or aspirin), for more than 10 days per month, unless they completed 
a 30-day washout period, or if they had a history of chronic inflammatory bowel 
disease, prior pelvic irradiation, or a history of endoscopically confirmed peptic 
ulcer disease within 5 years of enrollment. Neither dose of curcumin reduced 
PGE2 or 5-HETE in ACF or normal mucosa, nor did it reduce Ki-67 in normal 
mucosa, but the group receiving 4 g oral curcumin experienced a significant 
decrease in the number of ACF. After treatment, the reduction in ACF in this 
group was associated with a fivefold increase in serum curcumin or curcumin 
conjugates levels.
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8.2  Effects of curcumin supplementation in patients with polycystic ovary 
syndrome
Heshmati et al. investigated the effect of curcumin supplementation on fasting 
blood glucose, insulin resistance, and androgen levels in patients with polycystic 
ovary syndrome [44]. In a randomized double-blind placebo-controlled trial, 
72 women with polycystic ovary were enrolled. The study included women with 
PCOS aged 18–49 years (considered to be of reproductive age) who had a defini-
tive diagnosis of PCOS for at least two years (made by a specialist physician during 
the mild to moderate phase), had impaired glucose tolerance (IGT), were a user 
of only one of the metformin or clomiphene drug groups, and had a body mass 
index (BMI) greater than 25 but less than 30. Patients were excluded if they had 
any of the following: a) Other hormonal diseases/disorders, autoimmune diseases, 
cancer, inflammatory disease, infections, pregnancy, or lactation, b) use of mul-
tivitamin-mineral, omega3, polyphenolic, or antioxidant supplements, as well as 
anticoagulants such as heparin and warfarin or aspirin, blood cholesterol-lowering 
drugs (statins), or non-steroidal anti-inflammatory drugs (NSAIDs). Curcumin 
capsules containing 500 mg curcumin powder were given to the intervention 
group, while maltodextrin capsules containing 500 mg maltodextrin were given to 
the placebo group. For 12 weeks, participants took three capsules daily (1500 mg 
total). The trial’s primary outcomes were changes in fasting plasma glucose (FPG), 
fasting insulin (FI), sex hormones (Estradiol, Dehydroepiandrosterone (DHEA), 
Follicle-Stimulating Hormone (FSH), and Luteinizing Hormone (LH), and the 
modified Ferriman-Gallwey (mFG) hirsutism questionnaire. Changes in waist 
circumference (WC), weight, and body mass index were secondary outcomes of 
this study (BMI). At the conclusion of the study, it was observed that FPG and 
Dehydroepiandrosterone levels had decreased significantly, whereas Estradiol levels 
had increased statistically non-significantly in the intervention group following oral 
curcumin administration, in comparison to the placebo control group. At the end of 
the study, the authors concluded that curcumin is a safe and useful supplement for 
the treatment of PCOS-associated symptoms.
8.3 Curcumin in radiation dermatitis
One of the most common side effects experienced by patients suffering from 
cancers of sarcoma, breast, lung, and head and neck cancer and receiving radio-
therapy (RT) is radiation dermatitis. Because the skin is a highly proliferative and 
self-renewing organ, it is particularly susceptible to damage from ionizing radia-
tion, and as a result, the majority of patients undergoing radiotherapy develop 
radiation-induced skin reactions. Following dose- and time-dependent standard 
fractionation regimens in conventional radiotherapy, an accumulation of basal 
keratinocyte loss and impairment of the epidermal skin barrier occurs. The sever-
ity of radiation dermatitis varies from mild to severe erythema to dry or moist 
desquamation and ulceration. The current clinical guidelines for radiation-induced 
skin reactions include the following: 1) washing with lukewarm water and a mild 
soap; 2) applying unscented, lanolin-free, water-based moisturizers; and 3) IMRT. 
There is, however, no consensus regarding an agent capable of effectively reducing 
or preventing radiation dermatitis. Due to the fact that curcumin is a potent antioxi-
dant and anti-inflammatory agent that has long been used to treat skin conditions 
and wound healing, Ryan et al. conducted a randomized, double-blind, placebo-
controlled clinical trial to evaluate curcumin’s ability to reduce the severity of radia-
tion dermatitis in 30 breast cancer patients [45]. Individuals over the age of 18 years 
who have been diagnosed with noninflammatory breast cancer or carcinoma in situ 
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and have been prescribed RT without concurrent chemotherapy were included in 
the study. Patients were excluded if they had bilateral breast cancer; had received 
prior radiation to the chest or breast area; had undergone breast reconstruction 
and/or expanders prior to RT; were on anticoagulant (warfarin, coumadin, or 
heparin) or anti-epidermal growth factor receptor (EGFR) therapy; or had received 
partial breast irradiations. All patients received standard fractionated radiotherapy 
(1.8–2.4 Gy per session) for four to seven weeks, with or without boost, for a total 
dose of 42 Gy. The intervention group received four 500 mg curcumin capsules 
(Curcumin C3 complex, Sabsina) three times daily during the course of RT pre-
scribed. The control group received identical placebo capsules containing dicalcium 
phosphate 500 mg, excipients, and a yellow food coloring. Curcumin treatment was 
found to be more effective than placebo at reducing Radiation Dermatitis Severity 
(RDS) at the conclusion of treatment.
8.4 Curcumin in oral leukoplakia
Oral leukoplakia is a potentially malignant lesion of the oral cavity, for which no 
effective treatment is available. Kuriakose et al. conducted a Phase IIB Randomized 
Double-Blind Placebo-Controlled Trial to determine the efficacy of Curcumin in 
the treatment of Oral Leukoplakia [46]. After establishing eligibility and perform-
ing a baseline clinical examination, all subjects underwent lesion incision biopsy 
using a 5 mm punch biopsy. Subjects with a clinical and histologic diagnosis of 
leukoplakia, as well as other inclusion/exclusion criteria, were randomly assigned to 
receive either placebo or curcumin (three 600 mg capsules) twice daily after food 
for six months. At the conclusion of the study, physical examinations and labora-
tory tests, including complete blood count, serum biochemistry, and urine analysis, 
were performed at baseline, six months after randomization, and twelve months 
after randomization, respectively. The study concluded at the conclusion of the 
study period that curcumin was well tolerated, with combined clinical and histo-
logic response assessments indicating a significantly better response with curcumin 
treatment compared to placebo.
8.5 Efficacy of curcumin in cancer patients
Saghatelyanet al. conducted a randomized, double-blind, placebo-controlled, 
parallel-group clinical trial to determine the efficacy and safety of an intravenous 
infusion of curcumin in combination with paclitaxel in patients with metastatic 
or advanced breast cancer [47]. The eligible patients were randomly assigned to 
one of two study groups: curcumin + paclitaxel (curcumin group) or paclitaxel + 
placebo (placebo group). Paclitaxel (80 mg/m2) plus curcumin (CUC-1*, 300 mg 
solution, once weekly) were administered intravenously to the curcumin group for 
12 weeks with a 3-month follow-up. For the same period, the placebo group received 
paclitaxel plus a solution of riboflavin (200 mg in 20 ml). The study concluded 
that curcumin treatment had a significantly higher Objective Response Rate than 
placebo at four weeks of follow-up and was even better for patients who completed 
the treatment. Curcumin had a superior effect over placebo in both patients who 
completed the treatment and 3 months later. There were no other significant differ-
ences between the curcumin and placebo groups except that patients self-reported 
significantly greater physical performance with curcumin than with placebo during 
treatment and at the end of the follow-up, implying improved Paclitaxel tolerance 
in the curcumin group.
Choi et al. conducted a randomized, double-blind, placebo-controlled trial to 
determine the effect of curcumin on the duration of the first off-treatment, the 
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change in PSA and testosterone levels, the rate of PSA progression, and health-
related quality of life scores in patients with prostate cancer receiving intermittent 
androgen deprivation (IAD) [48]. The study included patients with prostate cancer 
who were treated with IAD for I biochemical recurrence (BCR) following localized 
therapy (eg, radical prostatectomy, radiation therapy, and high intensity focused 
ultrasound) or (ii) metastatic prostate cancer at initial diagnosis. All participants 
in this study received at least six months of treatment with an LHRH agonist and 
anti-androgens and entered the ADT withdrawal (off-treatment) period after 
a minimum of three months of maintaining a stable PSA nadir level. Exclusion 
criteria included prior use of an IAD for prostate cancer, hypersensitivity to 
curcumin, prior use of dietary supplements containing curcumin or turmeric to 
treat or prevent prostate cancer within the preceding six months of enrollment, 
and serious medical or psychological conditions (including impaired liver, kidney, 
cardiac, or hematopoietic functions) other than prostate cancer. The patients were 
randomly assigned to receive either a placebo or curcumin (240 mg of curcuminoid 
powder in capsule form), which was administered as two capsules three times daily 
(1440 mg/day) for six months following the cessation of ADT. The study concluded 
that during the six-month active treatment period, the proportion of patients with 
PSA progression was significantly lower in the Curcumin treatment group than in 
the placebo treatment group. The change in PSA, testosterone levels, and HRQOL 
scores after six months were comparable between the curcumin and placebo 
groups, but adverse events were more prevalent in the placebo group than in the 
curcumin group.
8.6 Effect of curcumin treatment in arthritis
Amalraj et al. conducted a randomized, double-blind, placebo-controlled, 
three-arm, parallel-group study to compare the efficacy of two different doses of 
curcumin to that of a placebo in patients with active rheumatoid arthritis (RA) 
[49]. For 90 days, twelve patients in each group received a placebo, 250 or 500 mg 
of the curcumin product, respectively. The American College of Rheumatology 
(ACR) response, visual analogue scale (VAS), C-reactive protein (CRP), Disease 
Activity Score 28 (DAS28), erythrocyte sedimentation rate (ESR), and rheumatoid 
factor (RF) values were used to assess the patients’ responses. At the conclusion 
of the study, RA patients who received the curcumin product at low and high 
doses reported statistically significant improvements in their clinical symptoms. 
Significant changes in ESR, CPR, and RF values were observed in patients receiving 
the study product when compared to baseline and placebo. The results indicate that 
this novel curcumin in a turmeric matrix acts as an analgesic and anti-inflammatory 
agent in the treatment of rheumatoid arthritis at a dose as low as 250 mg twice daily, 
as demonstrated by significant improvement in ESR, CRP, VAS, RF, DAS28, and 
ACR responses when compared to placebo. Both doses of the study product were 
well tolerated and were associated without any adverse events.
Fifty patients with Kellgren–Lawrence grade II or III knee osteoarthritis and 
a minimum age of 40 years were enrolled in a prospective, randomized, double-
blind, placebo-controlled clinical study [50]. For eight weeks, either a placebo or 
Theracurmin containing 180 mg/day of curcumin was administered orally. Blood bio-
chemistry analyses were performed before and after each intervention for the purpose 
of monitoring adverse events. The Japanese Knee Osteoarthritis Measure, the knee 
pain visual analogue scale (VAS), the Japanese Orthopedic Association’s knee scoring 
system, and the need for nonsteroidal anti-inflammatory drugs were used to evaluate 
the patients’ knee symptoms at 0, 2, 4, 6, and 8 weeks. At 8 weeks after treatment 
initiation, theracurmin-treated patients had significantly lower VAS scores for knee 
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pain than placebo-treated patients, except for those with initial VAS scores of 0.15 or 
less. Theracurmin significantly reduced celecoxib dependence compared to placebo. 
There were no significant adverse effects associated with Theracurmin treatment.
Osteoarthritis (OA) is a degenerative joint disease that is characterized by 
chronic and acute inflammation. Numerous studies have demonstrated curcumin’s 
anti-arthritic properties in humans with OA and rheumatoid arthritis (RA). In 
a six-week randomized double-blind placebo-controlled trial, 40 subjects with 
mild-to-moderate knee OA were randomly assigned to receive either curcuminoid 
(500 mg/day in three divided doses, n = 19) with 5 mg piperine added to each 
500-mg dose or a matched placebo (n = 21) [51]. Additionally, there was a reduc-
tion in systemic oxidative stress in subjects receiving the treatment compared to 
those receiving the placebo, as measured by serum SOD activity and concentrations 
of reduced GSH and malonedialdehyde (MDA). In a longer-term (eight months) 
randomized control trial, 50 subjects diagnosed with OA were randomly assigned 
to receive standard treatment plus two 500-mg tablets (Meriva®) daily containing 
a natural curcuminoid mixture (20%), phosphatidyl-choline (40%) and microcrys-
talline cellulose (40%) [52]. When comparing baseline to follow-up, the treatment 
group demonstrated significant decreases in all inflammation markers (soluble 
CD40 ligand (sCD40L), interleukin 1 beta (IL-1), interleukin 6 (IL-6), soluble 
vascular cell adhesion molecule 1 (sVCAM-1), and erythrocyte sedimentation rate 
(ESR), whereas the control group did not.
8.7 Effect of curcumin on inflammatory and metabolic disorders
Chronic low-grade inflammation is associated with the release of pro-inflamma-
tory cytokines, which results in Metabolic syndrome (MetS), which is defined by 
insulin resistance, hyperglycemia, hypertension, low high-density lipoprotein cho-
lesterol (HDL-C), elevated low-density lipoprotein cholesterol (LDL-C), elevated 
triglyceride levels, and obesity, particularly visceral obesity. These cytokines are 
thought to be at the root of diabetes and cardiovascular disease complications. For 
eight weeks, 117 subjects with MetS received either 1 g curcumin plus 10 mg piper-
ine to increase absorption or a placebo plus 10 mg piperine in a randomized double-
blind placebo-controlled trial with a parallel-group design. Following curcumin 
supplementation, serum concentrations of TNF- α, IL-6, transforming growth 
factor beta (TGF-b), and monocyte chemoattractant protein-1 (MCP-1) were 
significantly decreased. TGF-b serum levels were decreased in the placebo group, 
but not those of IL-6, TNF- α, or MCP-1. Between-group comparisons indicated 
that the curcumin group significantly reduced serum concentrations of TNF- α, 
IL-6, TGF-b, and MCP-1. Curcuminoids were found to be more effective than a 
placebo at lowering serum LDL-C, non-HDL-C, total cholesterol, triglycerides, and 
lipoprotein a (Lp (a)), as well as elevating HDL-C concentrations. Additionally, 
there was a significant improvement in serum SOD activity, reduced MDA, and 
C-reactive protein (CRP) concentrations in the group receiving curcumin with 
piperine compared to the placebo group, and the authors concluded that short-term 
supplementation with a curcuminoid-piperine combination significantly improves 
oxidative and inflammatory status [53–55].
A double-blind, randomized pilot study was conducted on 31 hemodialysis HD 
patients and divided them into two groups: the curcumin group (receiving 100 mL 
of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/
week for three months) and the control group (receiving the same juice without 
curcumin). After three months of supplementation, the curcumin group demon-
strated a significant decrease in NF-kB mRNA expression (AU) and plasma high 
sensitivity C-reactive protein (hsCRP) levels [56].
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Cicero et al. conducted a randomized double-blind placebo-controlled trial in 
which 80 overweight subjects with suboptimal fasting plasma glucose were ran-
domly assigned to receive 2 capsules of 800 mg phytosomal curcumin (Curserin®: 
200 mg) [57]. The study included individuals aged 18 to 70 years, with a body mass 
index (BMI) of between 25 and 30 kg/m2, and FPG levels of between 100 and 
125 mg/dL. Subjects were excluded if they had a personal history of cardiovascular 
disease or a risk factor for coronary heart disease, were taking glucose-lowering 
medications (oral antidiabetics, insulins), lipid-lowering medications (statins, 
fbrates, ezetimibe, omega-3 polyunsaturated fatty acids), or were taking drugs that 
affect lipid metabolism (i.e., full-dose thiazides, corticosteroids, or immunosup-
pressants), or After 56 days of treatment, it was observed that the curcumin-treated 
group had a significant improvement in fasting plasma insulin (FPI), HOMA index, 
waist circumference, blood pressure, triglycerides (TG), HDL-C, liver transami-
nases, gamma-GT, index of liver steatosis, and serum cortisol, when compared 
to the baseline. Additionally, FPI, TG, liver transaminases, fatty liver index, and 
serum cortisol levels improved significantly when compared to the placebo-treated 
group. In comparison to the baseline, the placebo group improved only in FPG and 
TG at the study’s conclusion. In conclusion, the trial demonstrated that supplemen-
tation with a phytosomal curcumin preparation containing phosphatidylserine and 
piperine could improve glycemic factors, hepatic function, and serum cortisol levels 
in overweight subjects with impaired fasting glucose.
Satoskar et al. investigated the effect of curcumin on spermatic cord edoema 
following surgery. Forty-five patients (ages 15–68) received 400 mg curcumin 
(Group A), 250 mg lactose powder placebo (Group B), or 100 mg phenylbutazone 
(Group C) thrice daily for six days following inguinal hernia or hydrocele repair 
[58]. The spermatic cord edoema, spermatic cord tenderness, operative site pain, 
and operative site tenderness were all recorded and graded on a scale of 0-3 
(0, absent, 1, mild, 2, moderate, 3, severe). The overall effect of treatment was 
determined by calculating the intensity score (TIS) for each group ranging from 0 
to 12. Curcumin treatment resulted in an 84.2% reduction in TIS. TIS was reduced 
by 61.8% and 86%, respectively, with placebo and phenylbutazone treatments. 
Although phenylbutazone treatment reduced TIS to a comparable extent on day 
6, it did not alleviate tenderness at the operative site. In comparison, Curcumin 
treatment was superior because it resulted in a decrease in all four inflammatory 
parameters.
Holt et al. studied ten patients aged 28 to 54 years to determine curcumin’s 
therapeutic effect in the treatment of inflammatory bowel disease (IBD) [59]. 
Crohn’s disease (CD) and ulcerative colitis (UC) are the two most common types 
of inflammatory bowel disease (IBD). Both are characterized by abdominal pain, 
vomiting, diarrhea, bloody stools, and weight loss, as well as secondary complica-
tions such as arthritis, pyoderma gangrenosum, and primary sclerosing cholangitis. 
Five patients with rectal UC were given 550 mg curcumin twice daily for one month 
and then three times daily for another month. The remaining five Crohn’s disease 
patients received 360 mg curcumin three times daily for one month and then four 
times daily for an additional month. At baseline and at the end of the study period, 
hematological and biochemical blood analysis, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), sigmoidoscopy, and biopsy were performed on 
the first group of patients. The second group of patients had their Crohn’s Disease 
Activity Index (CDAI), CRP, ESR, hematological blood analysis, and kidney func-
tion evaluated. All five patients in the first group improved by the end of the study 
period, as measured by a global score, and all five subjects had normal ESR, CRP, 
and serologic indices of inflammation after two months of curcumin treatment. 
CDAI scores decreased by an average of 55 points in the CD group, and CRP and 
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ESR levels decreased in four of five patients. CDAI scores decreased by an average 
of 55 points in the second group, while CRP and ESR levels decreased in four of five 
patients.
8.8 Efficacy of curcumin in the treatment of neurological and brain disorders
For an 18-month period, forty subjects (aged 51–84 years) were randomly 
assigned to receive a bioavailable form of curcumin [Theracurmin® containing 
90 mg of curcumin twice daily (N = 21)] or a placebo (N = 19). Verbal (Buschke 
Selective Reminding Test [SRT]) and visual (Brief Visual Memory Test-Revised 
[BVMT-R]) memory were used as primary outcomes, while attention (Trail 
Making A) was used as a secondary outcome to evaluate the efficacy and progress 
of treatment. FDDNP-PET signals in the amygdala, hypothalamus, medial and 
lateral temporal lobes, posterior cingulate, parietal, frontal, and motor regions 
were determined to measure the treatment outcomes and it was observed that in 
non-dementia adults, daily oral Theracurmin improves memory and attention. The 
FDDNP-PET results indicated that symptom improvement was associated with 
decreases in amyloid and tau accumulation in brain regions associated with mood 
and memory [60].
Numerous studies have confirmed curcumin’s antidepressant properties in 
patients with major depressive disorder. In one study, for 12 weeks, 123 individuals 
with major depressive disorder were randomly assigned to one of four treatment 
conditions: placebo, low-dose curcumin extract (250 mg), high-dose curcumin 
extract (500 mg), or a combination of low-dose curcumin extract and saffron 
(15 mg). Depressive symptoms were assessed for changes or improvements in 
comparison to placebo. The active drug treatments (when used in combination) 
were associated with significantly greater improvements in depressive symptoms 
and superior improvements in Spielberger State–Trait Anxiety Inventory STAI-state 
and STAI-trait scores compared to placebo. Active drug treatments were also more 
effective in people with atypical depression than in the general population. The 
study concluded that active drug treatments containing varying doses of curcumin 
and a combination of curcumin were effective at alleviating depressive and anx-
iolytic symptoms in people with major depressive disorder, with no significant 
differences observed between the varying curcumin doses [61].
Another study enrolled forty patients who had just experienced their first 
episode of depression in a 5-week, double-blind, randomized, placebo-controlled 
clinical trial. Subjects received either 500 mg/d curcumin or a placebo in combi-
nation with antidepressants (escitalopram or venlafaxine). The Clinical Global 
Impression—Severity Scale, Hamilton Depression Rating Scale, and Montgomery-
Asberg Depression Rating Scale were used as outcome measures. The analysis of 
variance revealed that both groups experienced significant positive changes in all 
scales of measurement from baseline to the end of the study. These changes became 
noticeable following the first visit following seven days of treatment. There was 
no statistically significant difference between curcumin and a placebo. However, 
patients in the curcumin group experienced a trend toward a faster resolution of 
depressive symptoms than those in the placebo group [62].
In a population of community-dwelling older adults, a 12-month, randomized, 
placebo-controlled, double-blind study was conducted to determine the ability of a 
curcumin formulation to prevent cognitive decline. For 12 months, participants (n 
96) were randomly assigned to receive placebo or 1500 mg/d BiocurcumaxTM. At 
baseline and at the 6-month and 12-month follow-up assessments, a battery of clini-
cal and cognitive measures was administered. Although no differences in clinical or 
cognitive measures were observed between the groups, a significant time treatment 
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group interaction was observed for the Montreal Cognitive Assessment (repeated 
measures analysis), which revealed a decline in function in the placebo group at 
6 months that was not observed in the curcumin treatment group [63].
A 24-week, double-blind, randomized, placebo-controlled study with thirty-
eight patients with chronic schizophrenia was conducted [64]. Subjects received 
either 3000 mg/d curcumin or a placebo in combination with antipsychotics. 
Positive and Negative Symptoms Scale (PANSS) and Calgary Depression Scale for 
Schizophrenia were used as outcome measures. The analysis of variance revealed 
that both groups experienced significant improvements in all scales of measure-
ment from the baseline period to the study’s conclusion. Within six months, 
curcumin produced a significant improvement in the total PANSS and the negative 
symptoms subscale. There were no differences between the treatment and placebo 
groups in terms of the positive and general PANSS subscales, as well as the Calgary 
Depression Scale for Schizophrenia scores.
A study examining the efficacy of curcumin oral supplementation in 
Amyotrophic Lateral Sclerosis randomly assigned patients to one of two groups: one 
that received a placebo for three months, followed by three months of curcumin 
oral supplementation (600 mg/day, Brainoil); and the second group that received 
curcumin oral supplementation (600 mg/day, Brainoil) for six months [65]. The 
evaluations were conducted at baseline (T0), three months after receiving either 
Brainoil or a placebo, and three months after the open-label phase. During an 
incremental forearm exercise test, clinical evaluations and measurement of oxida-
tive stress biomarkers such as oxidative protein products (AOPPs), ferric reducing 
ability (FRAP), total thiols (T-SH), and lactate were compared to a control group 
and the study found that the ALS-FRS-r score in the first group decreased, whereas 
the second group maintained a stable ALS-FRS-r score. Additionally, while FRAP 
exercise values remained stable in the second group, they decreased in the first 
group without treatment, after 3 months into the study. The entire ALS population 
demonstrated increased oxidative stress when compared to controls, with those 
treated with curcumin in the second group exhibiting decreased exercise AOPPs 
with values comparable to controls.
9. Conclusion
Turmeric has been used in our traditional system of medicine for centuries 
in treating some of the common health related problems in children and elderly 
individuals. For example when children catch cold and cough and get fever thou-
sands of mothers and grandmothers have given them a tea spoon full of turmeric 
suspended in milk to drink in the night before going to bed and invariably most of 
the children recover overnight. This has become an age old practice in Indian house 
hold for hundreds of years and there is no record how many children and elderly 
persons have benefited by this. At that time no one knew how turmeric worked and 
the modern medicine which the medicinal chemists think is their contribution was 
not even born. But since it had worked, even today a mother in an Indian village 
would prefer to give turmeric rather than an antibiotic to their children to control 
fever and cold. When children get infested with worms and their health deterio-
rates, mothers again give them turmeric orally for few days and children get cured 
and remain healthy. The modern medicinal chemistry has provided medicines like 
Albindazole which of course works but is toxic and children tend to get reinfected. 
Turmeric modulates the immune system and provides protection against reinfec-
tion. When children get wounded while playing mothers apply a paste of turmeric 
in some oil to the wound and it heals the wound very efficiently. Now modern 
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science has to give us answers to how this works rather than dismissing all these 
observations just because curcumin is unstable and cannot be a lead candidate. 
Even clinical trials, several of which have worked under double blind and placebo 
controlled conditions illustrate that curcuminoids, inspite of being unstable, can 
alleviate inflammatory conditions in several chronic disease conditions in humans. 
Therefore there is an intensive need to study Curcuminoids further and develop 
formulations which will help humans to combat severe overwhelming diseases.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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